Maze Therapeutics president sells $445,620 in company stock

Harold Bernstein, President, R&D & CMO at Maze Therapeutics, Inc., sold 16,142 shares of the company's common stock on August 13, 2026, for $445,620. The shares were traded at prices between $27.17 and $28.00, with an average price of $27.6063 per share. Despite a 101% return on investment over the past year, Maze Therapeutics' stock is currently trading below its 52-week high of $53.65.

According to InvestingPro analysis, the company is considered overvalued at present levels. This sale was made under a pre-established Rule 10b5-1 trading plan adopted by Mr. Bernstein on September 29, 2025. Before the sale, Bernstein purchased an equal number of shares through stock option exercise on the same date. These shares cost him $168,199, with a price of $10.42 per share.

The options were vested over time, with 25% vesting on October 3, 2023, and the remaining 75% vesting monthly. After these transactions, he holds 176,803 stock options. Maze Therapeutics has a market capitalization of $1.54 billion, and InvestingPro provides additional insights into the company's financial health and future growth.